Home › Cancro ai polmoni › Virginia
Studi clinici su Cancro ai polmoni nello stato di Virginia
58 studi su Cancro ai polmoni cercano partecipanti presso sedi nello stato di Virginia.
Città nello stato di Virginia
- Arlington41 studi
- Richmond14 studi
- Charlottesville13 studi
- Alexandria7 studi
- Winchester4 studi
- Lynchburg3 studi
- Norfolk3 studi
Testo ufficiale dello studio (inglese)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Ballad Health Cancer Care - Bristol, Bristol
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- e altri 7
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Virginia Cancer Specialists (VCS) ( Site 0408), Fairfax
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06780098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- e altri 7
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
- e altri 1
In reclutamentoFase 3
Età 70 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- University of Virginia Cancer Center, Charlottesville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT04181060Empathic Communication Skills (ECS) Training
- Chesapeake Regional Healthcare (Data Collection Only), Chesapeake
In reclutamentoVolontari sani benvenuti
Età da 18 a 100 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05456841Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- Virginia Cancer Institute, Richmond
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06765109Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07127874Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Inova Schar Cancer Infusion Pharmacy, Fairfax
- Inova Schar Cancer, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07519655Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Virginia Commonwealth University, Richmond
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07063745Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Fairfax
In reclutamentoFase 2
Età da 18 a 95 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax
- VCU Massey Cancer Center, Richmond
- e altri 1
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University of Virginia Health System, Charlottesville
- Virginia Commonwealth University (Vcu), Richmond
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07100080A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Next Oncology Virginia Cancer Specialist, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NEXT - Virginia, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07349537Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06287775BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07625644Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NEXT Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Virginia Oncology Associates, Norfolk
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Virginia Health System, Charlottesville
- USO - Virginia Cancer Specialists, Fairfax
- VCU Health Adult Outpatient Pavillion, Richmond
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- USO-Virginia Cancer Specialists, PC, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06561685Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
- University of Virginia Cancer Center, Charlottesville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07012031AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Fairfax
In reclutamentoFase 1/2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07038343Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- NEXT Oncology, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06343402The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- e altri 5
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06995898Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Shenandoah Oncology, P.C., Winchester
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07185997Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
- Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg
- Virginia Commonwealth University School of Medicine, Richmond
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT06712355Health Education Approach to Lung Screening
- Virginia Commonwealth University, Richmond
In reclutamentoVolontari sani benvenuti
Età da 50 a 80 · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT06070870Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Inova Alexandria Hospital, Alexandria
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06500481Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT07444814A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NEXT Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 lug 2026 · NCT05652686Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- NEXT Virginia, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 lug 2026 · NCT07315113Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- NEXT Oncology Virginia, Fairfax
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 giu 2026 · NCT06162221A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- NEXT Virginia, Fairfax
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT07458347Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.